AZN Astrazeneca PLC stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026Astrazeneca PLC (AZN) closed at $186.43 (-0.22%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 69, RS Rating 99, -12.3% from its 52-week high, +102.8% year to date. Sector: Healthcare · Drug Manufacturers - General.
AZN technical analysis
Trend
AZN's moving averages are mixed — no clean uptrend or downtrend. It closed 12.0% above the 50-day ($166.47) and 5.1% above the 200-day ($177.41). ADX(14) at 26 points to a strong, established trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 69, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $589.0M a day on average. ATR(14) is $4.70, 2.5% of price — its typical daily range.
Key levels
The chart pattern's support is $154.41 and its resistance $181.15. The 52-week range is $83.37 to $212.71; price is 12.3% below the high and 123.6% above the low. The VWAP anchored at the 52-week high is $175.70, below price.
Performance
AZN returned -0.1% (1 week), +17.4% (1 month), +15.1% (3 months), +2.0% (6 months), +129.7% (1 year), +102.8% (year to date).
About Astrazeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Drug Manufacturers - General · Listed 2009 · 96,100 employees
Congress activity
Disclosed STOCK Act trades in AZN · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Alan Armstrong senate · R · OK · traded 2026-03-31 | Buy | $1K–$15K | 2026-03-31 | 2026-07-21 | |
Alan Armstrong senate · R · OK · traded 2026-03-30 | Buy | $15K–$50K | 2026-03-30 | 2026-07-21 | |
 Julia Letlow house · LA · traded 2025-12-08 | Buy | $1K–$15K | 2025-12-08 | 2026-01-01 | |
 Gilbert Cisneros house · CA · traded 2025-11-19 | Buy | $1K–$15K | 2025-11-19 | 2025-12-12 | |
 Lisa McClain house · MI · traded 2025-10-30 | Buy | $1K–$15K | 2025-10-30 | 2025-11-01 | |
 Valerie Hoyle house · D · OR · traded 2025-09-23 | Sell | $1K–$15K | 2025-09-23 | 2025-10-10 | |
Valerie Hoyle house · D · OR · traded 2024-10-29 | Buy | $1K–$15K | 2024-10-29 | 2025-09-12 | |
Lisa McClain house · R · MI · traded 2025-06-17 | Sell | $1K–$15K | 2025-06-17 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-09 | Buy | $1K–$15K | 2025-06-09 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-07-22 | Buy | $1K–$15K | 2025-07-22 | 2025-08-13 |
Insider activity
SEC Form 4 transactions in AZN · open-market 1 buy · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Sharma Mani See Remarks · Ordinary Shares · 2026-09-08 | Grant | 1 | $163 | 2026-09-08 | 2026-09-11 |
Sharma Mani See Remarks · Ordinary Shares · 2026-08-08 | Buy | 20.233 | $3K | 2026-08-08 | 2026-09-11 |
Sharma Mani SVP, Group Controller · Ordinary Shares · 2026-08-06 | Grant | 2 | $327 | 2026-08-06 | 2026-08-07 |
Sharma Mani See Remarks · Ordinary Shares · 2026-07-06 | Grant | 2 | $381 | 2026-07-06 | 2026-07-08 |
Sharma Mani See Remarks · Ordinary Shares · 2026-06-08 | Grant | 1 | $180 | 2026-06-08 | 2026-06-16 |
Sharma Mani See Remarks · Ordinary Shares · 2026-05-20 | Sell | 11.89K | $2.2M | 2026-05-20 | 2026-05-22 |
Sharma Mani See Remarks · Ordinary Shares · 2026-05-06 | Grant | 1 | $186 | 2026-05-06 | 2026-05-08 |
Sharma Mani See Remarks · Ordinary Shares · 2026-04-07 | Grant | 1 | $196 | 2026-04-07 | 2026-05-08 |
SEC filings
EDGAR filings in AZN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.